CN120860031A - 抗生素组合疗法 - Google Patents

抗生素组合疗法

Info

Publication number
CN120860031A
CN120860031A CN202511016208.7A CN202511016208A CN120860031A CN 120860031 A CN120860031 A CN 120860031A CN 202511016208 A CN202511016208 A CN 202511016208A CN 120860031 A CN120860031 A CN 120860031A
Authority
CN
China
Prior art keywords
rifabutin
antibiotic
colistin
acinetobacter baumannii
antibiotics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511016208.7A
Other languages
English (en)
Chinese (zh)
Inventor
V·特雷博斯
C·凯默尔
G·E·戴尔
S·洛基乌罗
M·吉特青格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioversys AG
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CN120860031A publication Critical patent/CN120860031A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202511016208.7A 2019-09-12 2020-08-03 抗生素组合疗法 Pending CN120860031A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201962899257P 2019-09-12 2019-09-12
US62/899,257 2019-09-12
US201962902019P 2019-09-18 2019-09-18
US62/902,019 2019-09-18
US201962941160P 2019-11-27 2019-11-27
US62/941,160 2019-11-27
US202062977659P 2020-02-17 2020-02-17
US62/977,659 2020-02-17
CN202080077930.0A CN115052597B (zh) 2019-09-12 2020-08-03 抗生素组合疗法
PCT/IB2020/000645 WO2021048610A1 (en) 2019-09-12 2020-08-03 Antibiotic combination therapies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN202080077930.0A Division CN115052597B (zh) 2019-09-12 2020-08-03 抗生素组合疗法

Publications (1)

Publication Number Publication Date
CN120860031A true CN120860031A (zh) 2025-10-31

Family

ID=72432957

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202511016208.7A Pending CN120860031A (zh) 2019-09-12 2020-08-03 抗生素组合疗法
CN202080077348.4A Pending CN114980889A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202080077930.0A Active CN115052597B (zh) 2019-09-12 2020-08-03 抗生素组合疗法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202080077348.4A Pending CN114980889A (zh) 2019-09-12 2020-08-03 利福布汀治疗方法、用途和组合物
CN202080077930.0A Active CN115052597B (zh) 2019-09-12 2020-08-03 抗生素组合疗法

Country Status (17)

Country Link
US (6) US11207305B2 (enExample)
EP (3) EP4420673A3 (enExample)
JP (4) JP7769605B2 (enExample)
KR (1) KR20220103698A (enExample)
CN (3) CN120860031A (enExample)
AU (2) AU2020344214B2 (enExample)
BR (2) BR112022004645A2 (enExample)
CA (2) CA3154129A1 (enExample)
ES (1) ES2982067T3 (enExample)
HR (1) HRP20240818T1 (enExample)
HU (1) HUE066936T2 (enExample)
MX (1) MX2022003077A (enExample)
PH (1) PH12022550610A1 (enExample)
PL (1) PL4028001T3 (enExample)
RS (1) RS65681B1 (enExample)
SM (1) SMT202400250T1 (enExample)
WO (2) WO2021048611A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230364065A1 (en) 2022-05-16 2023-11-16 BioVersys AG Antibiotic combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645508B1 (en) * 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
CN101362067A (zh) * 2007-08-06 2009-02-11 天津科技大学 一种微胶囊制备方法
CA2714043C (en) * 2008-02-08 2016-11-08 Giaconda Limited Methods and compositions for treating inflammatory bowel disease
MY158809A (en) 2010-09-22 2016-11-15 Craun Res Sdn Bhd Pharmaceutical compositions for calanolides, their derivatives and analogues, and process for producing the same
EA016410B1 (ru) 2010-11-13 2012-04-30 Ооо "Нпк Наносистема" Фармацевтическая композиция на основе наночастиц циклодекстрина, содержащих рифабутин, способ ее получения, способ лечения микобактериоза и геликобактерной инфекции (варианты)
EP2670417A4 (en) * 2011-01-31 2014-07-09 Us Army METHOD AND COMPOSITIONS FOR TREATING BACTERIAL INFECTIONS WITH IRON RADIATORS
CN102178604B (zh) 2011-03-22 2014-03-05 中国人民解放军第三0九医院 凝胶微球制备装置、方法及可注射抗结核药物凝胶微球
RU2472512C1 (ru) * 2011-12-06 2013-01-20 Общество С Ограниченной Ответственностью "Ибмх-Экобиофарм" Противотуберкулезная композиция и способ ее получения
WO2016013986A1 (en) * 2014-07-25 2016-01-28 Agency For Science, Technology And Research Antibiotic compositions for treating bacterial infections
HK1243740A1 (zh) * 2014-09-04 2018-07-20 Labrador Diagnostics Llc 病原体和抗微生物剂抗性检测
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
WO2016178240A1 (en) * 2015-05-04 2016-11-10 Gufic Biosciences Limited A freeze dried pharmaceutical formulation of rifabutin and process for preparation thereof
JP7072898B2 (ja) * 2016-08-16 2022-05-23 ユニバーシティ オブ ロチェスター ポリミキシンｂ／トリメトプリム系の治療薬を含有する医薬組成物
AU2018219149A1 (en) * 2017-02-07 2019-09-19 Unm Rainforest Innovations Isotope enhanced ambroxol for long lasting autophagy induction
US11701346B2 (en) * 2018-11-28 2023-07-18 University Of Southern California Rifabutin for the treatment of acinetobacter baumannii

Also Published As

Publication number Publication date
HRP20240818T1 (hr) 2024-10-11
AU2020347536B2 (en) 2025-09-25
JP7804570B2 (ja) 2026-01-22
US12257241B2 (en) 2025-03-25
ES2982067T3 (es) 2024-10-14
PL4028001T3 (pl) 2024-07-22
MX2022003077A (es) 2022-07-11
US20240041845A1 (en) 2024-02-08
JP2026016690A (ja) 2026-02-03
EP4420673A2 (en) 2024-08-28
US20210077471A1 (en) 2021-03-18
EP4028000A1 (en) 2022-07-20
US20220184048A1 (en) 2022-06-16
WO2021048610A1 (en) 2021-03-18
US20210077472A1 (en) 2021-03-18
PH12022550610A1 (en) 2023-03-13
CA3154317A1 (en) 2021-03-18
AU2020344214A1 (en) 2022-04-21
JP2022548252A (ja) 2022-11-17
BR112022004645A2 (pt) 2022-06-21
CA3154129A1 (en) 2021-03-18
KR20220103698A (ko) 2022-07-22
US11766425B2 (en) 2023-09-26
RS65681B1 (sr) 2024-07-31
SMT202400250T1 (it) 2024-07-09
CN114980889A (zh) 2022-08-30
CN115052597A (zh) 2022-09-13
AU2020344214B2 (en) 2026-01-22
US11833139B2 (en) 2023-12-05
US20230132691A1 (en) 2023-05-04
CN115052597B (zh) 2025-07-08
US11351158B2 (en) 2022-06-07
HUE066936T2 (hu) 2024-09-28
EP4420673A3 (en) 2024-11-06
EP4028001C0 (en) 2024-04-10
EP4028001B1 (en) 2024-04-10
AU2020347536A1 (en) 2022-04-14
JP2022551228A (ja) 2022-12-08
BR112022004672A2 (pt) 2022-06-07
WO2021048611A1 (en) 2021-03-18
EP4028001A1 (en) 2022-07-20
JP7769605B2 (ja) 2025-11-13
JP2025176113A (ja) 2025-12-03
US11207305B2 (en) 2021-12-28
US20250281469A1 (en) 2025-09-11

Similar Documents

Publication Publication Date Title
Hagel et al. Perioperative antibiotic prophylaxis and antimicrobial therapy of intra-abdominal infections
US20110257079A1 (en) Parenteral Combination Therapy for Infective Conditions With Drug Resistant Bacterium
JP5782615B2 (ja) オリタバンシンの単回用量を用いる治療の方法
US12370184B2 (en) Antibiotic combination therapies
JP2025176113A (ja) 抗生物質併用療法
Metallidis et al. Penetration of moxifloxacin and levofloxacin into cancellous and cortical bone in patients undergoing total hip arthroplasty
ES2690725T3 (es) Composiciones que comprenden cefepima y tazobactam
US20230364065A1 (en) Antibiotic combination therapies
Shamaei-Tousi et al. RESULTS FROM A PHASE 2 CLINICAL TRIAL FOR TREATMENT OF BONE AND JOINT INFECTIONS WITH AFABICIN, A FIRST-IN-CLASS SELECTIVE ANTI-STAPHYLOCOCCAL ANTIBIOTIC
Berrington et al. Treatment of Staphylococcus aureus endocarditis using moxifloxacin
Jackson et al. Double-blind comparison of Cephacetrile with Cephalothin/Cephaloridine
Inoshita et al. A randomized prospective study of oral levofloxacin vs intravenous flomoxef prophylaxis in postoperative infection after endoscopic sinus surgery
WO2011146255A1 (en) Combination therapy for the treatment of bacterial infections caused by acinetobacter baumannii
Wilson et al. A clinical trial of teicoplanin compared with a combination of flucloxacillin and tobramycin as antibiotic prophylaxis for cardiac surgery: the use of a scoring method to assess the incidence of wound infection
Zheng et al. Assessing morinidazole for surgical site infection in class III wounds prevention: a multi-centre, randomized, single-blind, parallel-controlled study
Suankratay et al. Effectiveness and Adverse Events of Generic and Original Imipenem/Cilastatin in Hospitalized Patients: The First Multicenter Non-Inferiority Study in Thailand
Nord Use of newer quinolones for the treatment of intraabdominal infections: Focus on clinafloxacin
DuPont Overview of clinical experience of pefloxacin in gastrointestinal infections
Furlanut et al. Guidelines on Antibiotic Combination in ICU Patients
Bassetti et al. Linezolid treatment of prosthetic hip infections due to methicillin-resistant Staphylococcus aureus (MRSA)
Weinstein Chairman's summary
Moreland Faropenem medoxomil reaches the CAP in RTIs
Johnson et al. In Vitro Activity of Tigecycline against Multi-Drug Resistant Acinetobacter from the TEST Program Worldwide
Stuart Moxifloxacin
BODMER ABL CLARKE

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination